Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes

References

• Aliff TB, Maslak PG, Jurcic JG, et al. (2003). Refractory Aspergillus pneumonia in patients with acute leukemia. Cancer 97:1025–32
   PubMed Web of Science ®Google Scholar
• Antachopoulos C, Meletiadis J, Sein T, et al. (2007). Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species. Antimicrob Agents Chemother 51:881–7
   PubMed Web of Science ®Google Scholar
• Antachopoulos C, Meletiadis J, Sein T, et al. (2008). Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. Antimicrob Agents Chemother 52:321–8
   PubMed Web of Science ®Google Scholar
• Arendrup MC, Garcia-Effron G, Lass-Florl C, et al. (2010). Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1 CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and IsoSensitest media. Antimicrob Agents Chemother 54:426–39
   PubMed Web of Science ®Google Scholar
• Arendrup MC, Perkhofer S, Howard SJ, et al. (2008). Establishing in vitro–in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. Antimicrob Agents Chemother 52:3504–11
   PubMed Web of Science ®Google Scholar
• Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. (2002). In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 46:245–7
   PubMed Web of Science ®Google Scholar
• Balani SK, Xu X, Arison BH, et al. (2000). Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab Dispos 28:1274–8
   PubMed Web of Science ®Google Scholar
• Beauvais A, Fontaine T, Aimanianda V, Latge JP. (2014). Aspergillus cell wall and biofilm. Mycopathologia 178:371–7
   PubMed Web of Science ®Google Scholar
• Beauvais A, Schmidt C, Guadagnini S, et al. (2007). An extracellular matrix glues together the aerial-grown hyphae of Aspergillus fumigatus. Cell Microbiol 9:1588–600
   PubMed Web of Science ®Google Scholar
• Bernard M, Latge JP. (2001). Aspergillus fumigatus cell wall: composition and biosynthesis. Med Mycol 39:9–17
   PubMed Web of Science ®Google Scholar
• Betts RF, Nucci M, Talwar D, et al. (2009). A multicenter, double-blind trial of high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 48:1676–84
   PubMed Web of Science ®Google Scholar
• Beyda ND, John J, Kilic A, et al. (2014). FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin Infect Dis 59:819–25
   PubMed Web of Science ®Google Scholar
• Bink A, Kucharikova S, Neirinck B, et al. (2012). The nonsteroidal anti-inflammatory drug diclofenac potentiates the in vivo activity of caspofungin against Candida albicans biofilms. J Infect Dis 206:1790–7
   PubMed Web of Science ®Google Scholar
• Bizerra FC, Melo AS, Katchburian E, et al. (2011). Changes in cell wall synthesis and ultrastructure during paradoxical growth effect of caspofungin on four different Candida species. Antimicrob Agents Chemother 55:302–10
   PubMed Web of Science ®Google Scholar
• Caillot D, Thiebaut A, Herbrecht R, et al. (2007). Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat Trial). Cancer 110:2740–6
   PubMed Web of Science ®Google Scholar
• Caspofungin Acetate. (2014a). FDA advisory committee meeting background. Available from: http://www.fda/gov/ohrms/dockets/ac/01/briefing/3676b1_02.pdf [last accessed 29 Sep 2014]
   Google Scholar
• Caspofungin (Cancidas®) Package Insert. (2014b). Whitehouse Station (NJ): Merck & Co., Inc.; 2014 September
   Google Scholar
• Chamilos G, Lewis RE, Albert N, Kontoyiannis DP. (2007). Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences. Antimicrob Agents Chemother 51:2257–9
   PubMed Web of Science ®Google Scholar
• Chandrasekar PH, Sobel JD. (2006). Micafungin: a new echinocandin. Clin Infect Dis 42:1171–8
   PubMed Web of Science ®Google Scholar
• Chiller T, Farrokhshad K, Brummer E, Stevens DA. (2001). The interaction of human monocytes, monocyte-derived macrophages, and polymorphonuclear neutrophils with caspofungin (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus. Diagn Microbiol Infect Dis 39:99–103
   PubMed Web of Science ®Google Scholar
• Chryssanthou E, Cuenca-Estrella M. (2002). Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J Clin Microbiol 40:3841–4
   PubMed Web of Science ®Google Scholar
• Clancy CJ, Huang H, Cheng S, et al. (2006). Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments. Antimicrob Agents Chemother 50:2569–72
   PubMed Web of Science ®Google Scholar
• Cleary JD, Garcia-Effron G, Chapman SW, Perlin DS. (2008). Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob Agents Chemother 52:2263–5
   PubMed Web of Science ®Google Scholar
• Clemons KV, Espiritu M, Parmar R, Stevens DA. (2006). Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob Agents Chemother 50:1293–7
   PubMed Web of Science ®Google Scholar
• Clemons KV, Martinez M, Chen V, et al. (2011a). Efficacy of anidulafungin and caspofungin against a caspofungin-resistant isolate of Candida albicans in a murine model. 21st European Congress of Clinical Microbiology and Infectious Diseases and 27th International Congress of Chemotherapy, Milan, Italy, Abstracts no. O483
   Google Scholar
• Clemons KV, Schwartz JA, Stevens DA. (2011b). Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis. Med Mycol 49:834–47
   PubMed Web of Science ®Google Scholar
• Clemons KV, Schwartz JA, Stevens DA. (2012). Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity. Antimicrob Agents Chemother 56:4439–49
   PubMed Web of Science ®Google Scholar
• Cornely OA, Bassetti M, Calandra T, et al. (2012). ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18(Suppl. 7):19–37
   PubMed Web of Science ®Google Scholar
• Cornely OA, Lasso M, Betts R, et al. (2007). Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother 60:363–9
   PubMed Web of Science ®Google Scholar
• Cornely OA, Vehreschild JJ, Vehreschild MJ, et al. (2011). Phase II dose escalation study of caspofungin for invasive aspergillosis. Antimicrob Agents Chemother 55:5798–803
   PubMed Web of Science ®Google Scholar
• Cota J, Carden M, Graybill JR, et al. (2006). In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility. Antimicrob Agents Chemother 50:3926–8
   PubMed Web of Science ®Google Scholar
• Cota JM, Grabinski JL, Talbert RL, et al. (2008). Increases in SLT2 expression and chitin content are associated with incomplete killing of Candida glabrata by caspofungin. Antimicrob Agents Chemother 52:1144–6
   PubMed Web of Science ®Google Scholar
• Cuenca-Estrella M, Gomez-Lopez A, Garcia-Effron G, et al. (2005). Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus. Antimicrob Agents Chemother 49:1232–5
   PubMed Web of Science ®Google Scholar
• Dannaoui E, Lortholary O, Dromer F. (2004). In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob Agents Chemother 48:970–8
   PubMed Web of Science ®Google Scholar
• Denning DW. (1997). Echinocandins and pneumocandins – a new antifungal class with a novel mode of action. J Antimicrob Chemother 40:611–14
   PubMed Web of Science ®Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP, et al., European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. (2008). Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813–21
   PubMed Web of Science ®Google Scholar
• Deresinski SC, Stevens DA. (2003). Caspofungin. Clin Infect Dis 36:1445–57
   PubMed Web of Science ®Google Scholar
• Di Bonaventura G, Spedicato I, Picciani C, et al. (2004). In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies. Antimicrob Agents Chemother 48:4453–6
   PubMed Web of Science ®Google Scholar
• Dimopoulou D, Hamilos G, Tzardi M, et al. (2014). Anidulafungin versus caspofungin in a mouse model of candidiasis caused by anidulafungin-susceptible Candida parapsilosis isolates with different degrees of caspofungin susceptibility. Antimicrob Agents Chemother 58:229–36
   PubMed Web of Science ®Google Scholar
• Douglas C. (2001). Fungal beta (1,3)-d-glucan synthesis. Med Mycol 39(Suppl. 1):55–66
   PubMed Web of Science ®Google Scholar
• Douglas CM, Foor F, Marrinan JA, et al. (1994). The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-β-d-glucan synthase. Proc Natl Acad Sci USA 91:12907–11
   PubMed Web of Science ®Google Scholar
• Douglas CM, D’Ippolito JA, Shei GJ, et al. (1997). Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother 41:2471–9
   PubMed Web of Science ®Google Scholar
• Dowell JA, Knebal W, Ludden T, et al. (2004). Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 44:590–8
   PubMed Web of Science ®Google Scholar
• Eggimann P, Garbino J, Pittet D. (2003). Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 3:685–702
   PubMed Web of Science ®Google Scholar
• Elefanti A, Mouton JW, Verweij PE, et al. (2013). Amphotericin B-and voriconazole–echinocandin combinations against Aspergillus spp.: effect of serum on inhibitory and fungicidal interactions. Antimicrob Agents Chemother 57:4656–63
   PubMed Web of Science ®Google Scholar
• Ernst EJ, Klepser ME, Pfaller MA. (2000). Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother 44:1108–11
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. (1998). Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 36:2950–6
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. (2003). In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 20:121–36
   PubMedGoogle Scholar
• Espinel-Ingroff A, Fothergill A, Fuller J, et al. (2011). Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 Document). Antimicrob Agents Chemother 55:2855–9
   PubMed Web of Science ®Google Scholar
• Fattinger K, Cattori V, Hagenbuch B, et al. (2000). Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides Oatp1 and Oatp2. Hepatology 32:82–6
   PubMed Web of Science ®Google Scholar
• Fink M, Zerlauth U, Kaulfersch C, et al. (2013). A severe case of haemodynamic instability during anidulafungin administration. J Clin Pharm Ther 38:241–2
   PubMed Web of Science ®Google Scholar
• Fiori B, Posteraro B, Torelli R, et al. (2011). In vitro activities of anidulafungin and other antifungal agents against biofilms formed by clinical isolates of different Candida and Aspergillus species. Antimicrob Agents Chemother 55:3031–5
   PubMed Web of Science ®Google Scholar
• Fleischhacker M, Radecke C, Schulz B, Ruhnke M. (2008). Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis. Eur J Clin Microbiol Infect Dis 27:127–31
   PubMed Web of Science ®Google Scholar
• Fortwendel JR, Juvvadi PR, Perfect BZ, et al. (2010). Transcriptional regulation of chitin synthases by calcineurin controls paradoxical growth of Aspergillus fumigatus in response to caspofungin. Antimicrob Agents Chemother 54:1555–63
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. (2011). Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:e56–93
   PubMed Web of Science ®Google Scholar
• Garcia-Agudo L, Garcia-Martos P, Martos-Canadas J, et al. (2012). Evaluation of the Sensititre Yeast One microdilution method for susceptibility testing of Candida species to anidulafungin, caspofungin, and micafungin. Rev Esp Quimioter 25:256–60
   PubMed Web of Science ®Google Scholar
• Gauthier GM, Nork TM, Prince R, Andes D. (2005). Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin Infect Dis 41:e27–8
   PubMed Web of Science ®Google Scholar
• Gonzalez GM, Tijerina R, Najvar LK, et al. (2001). Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model. Antimicrob Agents Chemother 45:1854–9
   PubMed Web of Science ®Google Scholar
• Graybill JR, Bocanegra R, Najvar LK, et al. (2003). Addition of caspofungin to fluconazole does not improve outcome in murine candidiasis. Antimicrob Agents Chemother 47:2373–5
   PubMed Web of Science ®Google Scholar
• Hakki M, Staab JF, Marr KA. (2006). Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother 50:2522–4
   PubMed Web of Science ®Google Scholar
• Hall RG 2nd, Swancutt MA, Meek C, et al. (2013). Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourths. Antimicrob Agents Chemother 57:2259–64
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Maertens J, Baila L, et al. (2010). Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organization for Research and Treatment of Cancer study. Bone Marrow Transplant 45:1227–33
   PubMed Web of Science ®Google Scholar
• Hohl TM, Feldmesser M, Perlin DS, Pamer EG. (2008). Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal β-glucan exposure. J Infect Dis 198:176–85
   PubMed Web of Science ®Google Scholar
• Hope WW, Castagnola E, Groll AH, et al. for the ESCMID Fungal Infection Study Group (EFISG) (2012). ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect 18:38–52
   PubMed Web of Science ®Google Scholar
• Joubert L-M., Ferreira JAG, Stevens DA, et al. (2015). Aspergillus fumigatus biofilms: a comparison of processing techniques for scanning electron microscopy of fungal mycelium and extracellular matrix. Microsc Microanal 21, in press
   Google Scholar
• Jullien V, Blanchet B, Benyamina M, et al. (2012). Pharmacokinetics of caspofungin in two patients with burn injuries. Antimicrob Agents Chemother 56:4550–1
   PubMed Web of Science ®Google Scholar
• Kahn JN, Garcia-Effron G, Hsu MJ, et al. (2007). Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother 51:1876–8
   PubMed Web of Science ®Google Scholar
• Kartsonis N, Killar J, Mixson L, et al. (2005). Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob Agents Chemother 49:3616–23
   PubMed Web of Science ®Google Scholar
• Kim T, Hong H-L, Lee Y-M, et al. (2013). Is caspofungin really an effective treatment for Pneumocystis jirovecii pneumonia in immunocompromised patients without human immunodeficiency virus infection? Experiences at a single center and a literature review. Scand J Infect Dis 45:484–8
   PubMed Web of Science ®Google Scholar
• Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. (2002). Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 46:2564–8
   PubMed Web of Science ®Google Scholar
• Klis FM, de Groot P, Hellingwerf K. (2001). Molecular organization of the cell wall of Candida albicans. Med Mycol 39(Suppl. 1):1–8
   PubMed Web of Science ®Google Scholar
• Koch C, Uhle F, Wolff M, et al. (2015). Cardiac effects of echinocandins after central venous administration in adult rats. Antimicrob Agents Chemother 59:1612–19
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Hachem R, Lewis RE, et al. (2003). Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98:292–9
   PubMed Web of Science ®Google Scholar
• Kucharikova S, Tournu H, Lagrou K, et al. (2011). Detailed comparison of Candida albicans and Candida glabrata biofilms under different conditions and their susceptibility to caspofungin and anidulafungin. J Med Microbiol 60:1261–9
   PubMed Web of Science ®Google Scholar
• Kucharikova S, Sharma N, Spriet I, et al. (2013). Activities of systemically administered echinocandins against in vivo mature Candida albicans biofilms developed in a rat subcutaneous model. Antimicrob Agents Chemother 57:2365–8
   PubMed Web of Science ®Google Scholar
• Lafaurie M, Lapalu J, Raffoux E, et al. (2010). High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia. Clin Micro Infect 16:1191–6
   PubMed Web of Science ®Google Scholar
• Lamaris GA, Lewis RE, Chamilos G, et al. (2008). Caspofungin-mediated β-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis 198:186–92
   PubMed Web of Science ®Google Scholar
• Lee KK, Maccallum DM, Jacobsen MD, et al. (2012). Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo. Antimicrob Agents Chemother 56:208–17
   PubMed Web of Science ®Google Scholar
• Lepak A, Castanheira M, Diekema D, et al. (2012). Optimizing echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations. Antimicrob Agents Chemother 56:5875–82
   PubMed Web of Science ®Google Scholar
• Lewis RE, Albert ND, Kontoyiannis DP. (2008). Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis. J Antimicrob Chemother 61:1140–4
   PubMed Web of Science ®Google Scholar
• Lichtenstern C, Wolff M, Arens C, et al. (2013). Cardiac effects of echinocandin preparations: three case reports. J Clin Pharm Ther 38:429–31
   PubMed Web of Science ®Google Scholar
• Louie A, Deziel M, Liu W, et al. (2005). Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 49:5058–68
   PubMed Web of Science ®Google Scholar
• Loussert C, Schmitt C, Prevost MC, et al. (2010). In vivo biofilm composition of Aspergillus fumigatus. Cell Microbiol 12:405–10
   PubMed Web of Science ®Google Scholar
• Madureira A, Bergeron A, Lacroix C, et al. (2007). Breakthrough invasive aspergillosis in allogeneic hematopoietic stem cell transplant recipients treated with caspofungin. Int J Antimicrob Agents 30:551–4
   PubMed Web of Science ®Google Scholar
• Maertens J, Glasmacher A, Herbrecht R, et al. (2006). Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 107:2888–97
   PubMed Web of Science ®Google Scholar
• Maertens J, Raad I, Petrikkos G, et al. (2004). Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39:1563–71
   PubMed Web of Science ®Google Scholar
• Maertens JA, Madero L, Reilly AF, et al. (2010). A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J 29:415–20
   PubMed Web of Science ®Google Scholar
• Manavathu EK, Ramesh MS, Baskaran I, et al. (2004). A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans. J Antimicrob Chemother 53:386–9
   PubMed Web of Science ®Google Scholar
• Marr KA, Boeckh M, Carter RA, et al. (2004a). Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 39:797–802
   PubMed Web of Science ®Google Scholar
• Marr KA, Hachem R, Papanicolaou G, et al. (2004b). Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporine A. Transpl Infect Dis 6:110–16
   PubMedGoogle Scholar
• Mavridou E, Meletiadis J, Rijs A, et al. (2015). The strength of synergistic interaction between posaconazole and caspofungin depends on the underlying azole resistance mechanism of Aspergillus fumigatus. Antimicrob Agents Chemother 59:1738–44
   PubMed Web of Science ®Google Scholar
• Mazur P, Morin N, Baginsky W, et al. (1995). Differential expression and function of two homologous subunits of yeast 1,3-β-d-glucan synthase. Mol Cell Biol 15:5671–81
   PubMed Web of Science ®Google Scholar
• Melo AS, Colombo AL, Arthington-Skaggs BA. (2007). Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species. Antimicrob Agents Chemother 51:3081–8
   PubMed Web of Science ®Google Scholar
• Migoya EM, Mistry GC, Stone JA, et al. (2011). Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants. J Clin Pharmacol 51:202–11
   PubMed Web of Science ®Google Scholar
• Mistry GC, Migoya E, Deutsch PJ, et al. (2007). Single-and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations. J Clin Pharmacol 47:951–61
   PubMed Web of Science ®Google Scholar
• Mora-Duarte J, Betts R, Rotstein C, et al. (2002). Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347:2020–9
   PubMed Web of Science ®Google Scholar
• Moudgal V, Little T, Boikov D, Vazquez JA. (2005). Multiechinocandin-and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 49:767–9
   PubMed Web of Science ®Google Scholar
• Mowat E, Lang S, Williams C, et al. (2008). Phase-dependent antifungal activity against Aspergillus fumigatus developing multicellular filamentous biofilms. J Antimicrob Chemother 62:1281–4
   PubMed Web of Science ®Google Scholar
• Munro CA, Selvaggini S, de Bruijn I, et al. (2007). The PKC, HOG, and Ca2+ signaling pathways co-ordinately regulate chitin synthesis in Candida albicans. Mol Microbiol 63:1399–413
   PubMed Web of Science ®Google Scholar
• Nagappan V, Boikov D, Vazquez JA. (2010). Assessment of the in vitro kinetic activity of caspofungin against Candida glabrata. Antimicrob Agents Chemother 54:522–5
   PubMed Web of Science ®Google Scholar
• Neely M, Jafri HS, Seibel N, et al. (2009). Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother 53:1450–6
   PubMed Web of Science ®Google Scholar
• Ngai AL, Bourque MR, Lupinacci RJ, et al. (2011). Overview of safety experience with caspofungin in clinical trials conducted over the first 15 years: a brief report. Int J Antimicrob Agents 38:540–4
   PubMed Web of Science ®Google Scholar
• Nguyen KT, Ta P, Hoang BT, et al. (2009). Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. Antimicrob Agents Chemother 53:3347–52
   PubMed Web of Science ®Google Scholar
• Nguyen TH, Hoppe-Tichy T, Geiss HK, et al. (2007). Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J Antimicrob Chemother 60:100–6
   PubMed Web of Science ®Google Scholar
• Nivoix Y, Velten M, Letscher-Bru V, et al. (2008). Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 47:1176–84
   PubMed Web of Science ®Google Scholar
• Odio CM, Araya R, Pinto LE, et al. (2004). Caspofungin therapy of neonates with invasive candidiasis. Pediat Infect Dis 23:1093–7
   Google Scholar
• O’Shaughnessy EM, Meletiadis J, Stergiopoulou T, et al. (2006). Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species. J Antimicrob Chemother 58:1168–76
   PubMed Web of Science ®Google Scholar
• Osherov N, May GS, Albert ND, Kontoyiannis DP. (2002). Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae. Antimicrob Agents Chemother 46:2462–9
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. (2003). Antifungal susceptibility survey of 2000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 47:3149–54
   PubMed Web of Science ®Google Scholar
• Paderu P, Park S, Perlin DS. (2004). Caspofungin uptake is mediated by a high-affinity transporter in Candida albicans. Antimicrob Agents Chemother 48:3845–9
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes D, et al. (2009). Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48:503–35
   PubMed Web of Science ®Google Scholar
• Pappas PG, Rotstein CM, Betts RF, et al. (2007). Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45:883–93
   PubMed Web of Science ®Google Scholar
• Park S, Kelly R, Kahn JN, et al. (2005). Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida spp. isolates. Antimicrob Agents Chemother 49:3264–73
   PubMed Web of Science ®Google Scholar
• Pasquale T, Tomada JR, Ghannoun MA, et al. (2008). Emergence of Candida tropicalis resistant to caspofungin [letter]. J Antimicrob Agents Chemother 61:219
   Web of Science ®Google Scholar
• Perea S, Gonzalez G, Fothergill AW, et al. (2002). In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 46:3039–41
   PubMed Web of Science ®Google Scholar
• Perlin DS. (2007). Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 10:121–30
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Boyken L, Hollis RJ, et al. (2006). In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol 44:760–3
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Boyken L, Hollis RJ, et al. (2008a). In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 46:150–6
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Boyken L, Hollis RJ, et al. (2009). In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method. J Clin Microbiol 47:3323–5
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Boyken L, Hollis RJ, et al. (2010). Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J Clin Microbiol 48:52–6
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Andes D, et al. (2011). Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 14:164–76
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, et al. (2008b). Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol 46:2620–9
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Boyken L, et al. (2004). Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3000 clinical isolates. J Clin Microbiol 42:3117–19
   PubMed Web of Science ®Google Scholar
• Pham CD, Iqbal N, Bolden CB, et al. (2014). Role of FKS mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrob Agents Chemother 58:4690–6
   PubMed Web of Science ®Google Scholar
• Popolo L, Gualtieri T, Ragni E. (2001). The yeast cell-wall salvage pathway. Med Mycol 39(Suppl. 1):111–21
   PubMed Web of Science ®Google Scholar
• Powles MA, Liberator P, Anderson J, et al. (1998). Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob Agents Chemother 42:1985–9
   PubMed Web of Science ®Google Scholar
• Prabhu RM, Orenstein R. (2004). Failure of caspofungin to treat brain abscesses secondary to Candida albicans prosthetic valve endocarditis. Clin Infect Dis [letter] 39:1253–4
   PubMed Web of Science ®Google Scholar
• Raad II, Hanna HA, Boktour M, et al. (2008). Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia 22:496–503
   PubMed Web of Science ®Google Scholar
• Ramage G, VandeWalle K, Bachmann SP, et al. (2002). In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother 46:3634–6
   PubMed Web of Science ®Google Scholar
• Reed C, Bryant R, Ibrahim AS, et al. (2008). Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 47:364–71
   PubMed Web of Science ®Google Scholar
• Reichhardt C, Ferreira JAG, Joubert L, et al. (2015). Analysis of the Aspergillus fumigatus biofilm extracellular matrix by solid-state nuclear magnetic resonance. Eukaryotic Cell. [Epub ahead of print]. doi: 10.1128/EC.00050-15
   Google Scholar
• Reminiac F, Sonneville R, Massias L, et al. (2014). Very-high-dose caspofungin combined with voriconazole to treat central nervous system aspergillosis: substantial penetration of caspofungin into cerebrospinal fluid. Antimicrob Agents Chemother 58:3568–9
   PubMed Web of Science ®Google Scholar
• Ricciardi A, Maffongelli G, Di Veroli A, et al. (2013). Caspofungin as salvage treatment in immunocompromised patients with Pneumocystis jiroveci pneumonia. 53rd Intersci Conf Antimicrob Agents Chemother, abstract no. M-240
   Google Scholar
• Rocha EM, Garcia-Effron G, Park S, Perlin DS. (2007). A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus. Antimicrob Agents Chemother 51:4174–6
   PubMed Web of Science ®Google Scholar
• Rueda C, Cuenca-Estrella M, Zaragoza O. (2014). Paradoxical growth of Candida albicans in the presence of caspofungin is associated with multiple cell wall rearrangements and decreased virulence. Antimicrob Agents Chemother 58:1071–83
   PubMed Web of Science ®Google Scholar
• Ryan DM, Lupinacci RJ, Kartsonis NA. (2011). Efficacy and safety of caspofungin in obese patients. Med Mycol 49:748–54
   PubMed Web of Science ®Google Scholar
• Saez-Llorens X, Macias M, Maiya P, et al. (2009). Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother 53:869–75
   PubMed Web of Science ®Google Scholar
• Sandhu P, Lee W, Xu X, et al. (2005). Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos 33:676–82
   PubMed Web of Science ®Google Scholar
• Saner F, Gensicke J, Rath P, et al. (2006). Safety profile of concomitant use of caspofungin and cyclosporine or tacrolimus in liver transplant patients. Infection 34:328–32
   PubMed Web of Science ®Google Scholar
• Sanz-Rodriguez C, Lopez-Duarte M, Jurado M, et al. (2004). Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplant 34:13–20
   PubMed Web of Science ®Google Scholar
• Sarkar S, Uppuluri P, Pierce CG, Lopez-Ribot JL. (2014). In vitro study of sequential fluconazole and caspofungin treatment against Candida albicans biofilms. Antimicrob Agents Chemother 58:1183–6
   PubMed Web of Science ®Google Scholar
• Schuetzer-Muehlbauer M, Willinger B, Krapf G, et al. (2003). The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin. Mol Microbiol 48:225–35
   PubMed Web of Science ®Google Scholar
• Seidler MJ, Salvenmoser S, Muller FMC. (2008). Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells. Antimicrob Agents Chemother 52:4130–6
   PubMed Web of Science ®Google Scholar
• Shen Y-C, Liang C-Y, Wang C-Y, et al. (2014). Pharmacokinetics and safety of intravitreal caspofungin. Antimicrob Agents Chemother 58:7234–9
   PubMed Web of Science ®Google Scholar
• Shields RK, Nguyen MH, Du C, et al. (2011). Paradoxical effect of caspofungin against Candida bloodstream isolates is mediated by multiple pathways but eliminated in human serum. Antimicrob Agents Chemother 55:2641–7
   PubMed Web of Science ®Google Scholar
• Shields RK, Nguyen MH, Press E, Clancy CJ. (2014). Abdominal candidiasis is a hidden reservoir of echinocandin resistance. Antimicrob Agents Chemother 58:7601–5
   PubMed Web of Science ®Google Scholar
• Shinde RB, Chauhan NM, Raut JS, Karuppayil SM. (2012). Sensitization of Candida albicans biofilms to various antifungal drugs by cyclosporine A. Ann Clin Microbiol Antimicrob 11:27--34
   PubMed Web of Science ®Google Scholar
• Simitsopoulou M, Peshkova P, Tasina E, et al. (2013). Species-specific and drug-specific differences in susceptibility of Candida biofilms to echinocandins: characterization of less common bloodstream isolates. Antimicrob Agents Chemother 57:2562–70
   PubMed Web of Science ®Google Scholar
• Singh G, Imai J, Clemons KV, Stevens DA. (2005). Efficacy of caspofungin against central nervous system Aspergillus fumigatus infection in mice determined by Taqman polymerase chain reaction and colony forming units methods. Antimicrob Agents Chemother 49:1369–76
   PubMed Web of Science ®Google Scholar
• Singh N, Limaye AP, Forrest G, et al. (2006). Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 81:320–6
   PubMed Web of Science ®Google Scholar
• Staab JF, Kahn JN, Marr KA. (2010). Differential Aspergillus lentulus echinocandin susceptibilities are Fksp independent. Antimicrob Agents Chemother 54:4992–8
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Schell WA, Blankenship JR, et al. (2004). In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. Antimicrob Agents Chemother 48:1664–9
   PubMed Web of Science ®Google Scholar
• Stevens DA. (2002). Drug interaction of caspofungin with conventional agents against pathogens of endemic mycoses. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Abstracts, no. M-863
   Google Scholar
• Stevens DA. (2008). A possible mechanism for synergy between antifungal therapy and immune defenses. J Infect Dis 198:159–62
   PubMed Web of Science ®Google Scholar
• Stevens DA. (2013). Reflections on the approach to treatment of a mycologic disaster. Antimicrob Agents Chemother 57:1567–72
   PubMed Web of Science ®Google Scholar
• Stevens DA, Espiritu M, Parmar R. (2004). Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother 48:3407–11
   PubMed Web of Science ®Google Scholar
• Stevens DA, Ichinomiya M, Koshi Y, Horiuchi H. (2006a). Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for β-1,6-glucan synthesis inhibition by caspofungin. Antimicrob Agents Chemother 50:3160–1
   PubMed Web of Science ®Google Scholar
• Stevens DA, McCullough MJ, Clemons KV, Martinez MC. (2006b). Candida dubliniensis, a species with an extremely high frequency of paradoxical effect with caspofungin. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Abstracts, no. M-1756
   Google Scholar
• Stevens DA, White TC, Perlin DS, Selitrennikoff CP. (2005). Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn Micro Infect Dis 51:173–8
   PubMed Web of Science ®Google Scholar
• Stone JA, Holland SD, Wickersham PJ, et al. (2002). Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 46:739–45
   PubMed Web of Science ®Google Scholar
• Stone JA, Migoya EM, Hickey L, et al. (2004a). Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother 48:4306–14
   PubMed Web of Science ®Google Scholar
• Stone JA, Xu X, Winchell GA, et al. (2004b). Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 48:815–23
   PubMed Web of Science ®Google Scholar
• Sun P, Tong Z. (2014). Efficacy of caspofungin, a 1,3-beta-D-glucan synthase inhibitor, on Pneumocystis carinii pneumonia in rats. Med Mycol 52:798–803
   PubMed Web of Science ®Google Scholar
• Tawara S, Ikeda F, Maki K, et al. (2000). In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 44:57–62
   PubMed Web of Science ®Google Scholar
• Thompson GR 3rd, Wiederhold NP, Vallor AC, et al. (2008). Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob Agents Chemother 52:3783–5
   PubMed Web of Science ®Google Scholar
• Utili R, Durante-Mangoni E, Basilico C, et al. (2007). Efficacy of caspofungin addition to trimethoprim-sulfamethoxazole treatment for severe Pneumocystis pneumonia in solid organ transplant recipients. Transplantation 84:1–4
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Akova M, Herbrecht R, et al. (2012). ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 18:53–67
   PubMed Web of Science ®Google Scholar
• van Asbeck EC, Hoepelman AI, Scharringa J, Verhoef J. (2008). The echinocandin caspofungin impairs the innate immune mechanism against Candida parapsilosis. Int J Antimicrob Agents 33:21–6
   PubMed Web of Science ®Google Scholar
• Venisse N, Gregoire N, Marliat M, Couet W. (2008). Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicans. Antimicrob Agents Chemother 52:937–43
   PubMed Web of Science ®Google Scholar
• Villanueva A, Gotuzzo E, Arathoon EG, et al. (2002). A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 113:294–9
   PubMed Web of Science ®Google Scholar
• Viscoli C, Herbrecht R, Akan H, et al. (2009). An EORTC phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 64:1274–81
   PubMed Web of Science ®Google Scholar
• Vitale RG, de Hoog GS, Schwarz P, et al. (2012). Antifungal susceptibility and phylogeny of opportunistic members of the order Mucorales. J Clin Microbiol 50:66–75
   PubMed Web of Science ®Google Scholar
• Walker LA, Gow NA, Munro CA. (2013). Elevated chitin content reduces the susceptibility of Candida species to caspofungin. Antimicrob Agents Chemother 57:146–54
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Adamson PC, Seibel NL, et al. (2005). Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 49:4536–45
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW, et al. (2008). Treatment of aspergillosis: clinical practice guidelines of the Infectious Disease Society of America. Clin Infect Dis 46:327–60
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Teppler H, Donowitz GR, et al. (2004). Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. New Engl J Med 351:1391–402
   PubMed Web of Science ®Google Scholar
• Wang JL, Chang CH, Young-Xu Y, Chan KA. (2010). Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Antimicrob Agents Chemother 54:2409–19
   PubMed Web of Science ®Google Scholar
• Weiler S, Seger C, Pfisterer H, et al. (2013). Pharmacokinetics of caspofungin in critically ill patients on continuous renal replacement therapy. Antimicrob Agents Chemother 57:4053–7
   PubMed Web of Science ®Google Scholar
• Wiederhold NP. (2009). Paradoxical echinocandin activity: a limited in vitro phenomenon? Med Mycol 47(Suppl. 1):5369–75
   Google Scholar
• Wiederhold NP, Grabinski JL, Garcia-Effron G, et al. (2008). Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. Antimicrob Agents Chemother 52:4145–8
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Kontoyiannis DP, Chi J, et al. (2004). Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 190:1464–71
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Kontoyiannis DP, Prince RA, Lewis RE. (2005). Attenuation of the activity of caspofungin at high concentrations against Candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob Agents Chemother 49:5146–8
   PubMed Web of Science ®Google Scholar
• Wurthwein G, Cornely OA, Trame MN, et al. (2013). Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis. Antimicrob Agents Chemother 57:1664–71
   PubMed Web of Science ®Google Scholar
• Zaoutis TE, Jafri HS, Huang LM, et al. (2009a). A prospective, multicenter, study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics 123:877–84
   PubMed Web of Science ®Google Scholar
• Zaoutis T, Lehrnbecher T, Groll AH, et al. (2009b). Safety experience with caspofungin in pediatric patients. Pediatr Infect Dis J 28:1132–5
   PubMed Web of Science ®Google Scholar